Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting

Authors not listed

Spanish Lung Cancer Group · 2017

Abstract

This is a multi-center phase II trial of intravenous (IV) Pembrolizumab MK-3475 in subjects older than 70 years with advanced Non-small cell Lung Cancer (NSCLC) expressing Programmed death-ligand 1 (PD-L1). 82 patients will be enrolled in this trial to examine the efficacy, the impact on geriatric assessments, the quality of life and the self-reported outcomes.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-19 MST

Cite this

APA
Anonymous. (2017). Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting. <em>Spanish Lung Cancer Group</em>. https://clinicaltrials.gov/study/NCT03293680
Vancouver
Anonymous. Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting. Spanish Lung Cancer Group. 2017.
BibTeX
@misc{anon2017Surviv, title = {Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting}, author = {Anonymous}, journal = {Spanish Lung Cancer Group}, year = {2017}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings